<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="publisher-id">GRP</journal-id><journal-title-group><journal-title>Gastroenterology Research and Practice</journal-title></journal-title-group><issn pub-type="ppub">1687-6121</issn><issn pub-type="epub">1687-630X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26064098</article-id><article-id pub-id-type="pmc">4434224</article-id><article-id pub-id-type="doi">10.1155/2015/818043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Standard Triple Therapy versus Sequential Therapy in <italic>Helicobacter pylori</italic> Eradication: A Double-Blind, Randomized, and Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8402-2033</contrib-id><name><surname>Eisig</surname><given-names>Jaime Natan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Navarro-Rodriguez</surname><given-names>Tom&#x000e1;s</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>Ana Cristina S&#x000e1;</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Fernando Marcuz</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mattar</surname><given-names>Rejane</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chinzon</surname><given-names>Decio</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Haro</surname><given-names>Christiane</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2427-7843</contrib-id><name><surname>Diniz</surname><given-names>M&#x000e1;rcio Augusto</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moraes-Filho</surname><given-names>Joaquim Prado</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fass</surname><given-names>Ronnie</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barbuti</surname><given-names>Ricardo Correa</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Gastroenterology and Clinical Hepatology, Hospital das Cl&#x000ed;nicas da FMUSP, 05493-900 S&#x000e3;o Paulo, SP, Brazil</aff><aff id="I2"><sup>2</sup>Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA</aff><author-notes><corresp id="cor1">*Jaime Natan Eisig: <email>eisig@uol.com.br</email></corresp><fn fn-type="other"><p>Academic Editor: Andrew S. Day</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>818043</elocation-id><history><date date-type="received"><day>5</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Jaime Natan Eisig et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Aim</italic>. To compare 10-day standard triple therapy versus sequential therapy as first-line treatment in patients infected with <italic>H. pylori</italic>. <italic>Methods</italic>. One hundred <italic>H. pylori</italic> positive patients (diagnosed by rapid urease test and histology), with average age of 47.2, M/F = 28/72, were randomized to receive either standard triple treatment (TT) as follows: lansoprazole 30&#x02009;mg, clarithromycin 500&#x02009;mg, and amoxicillin 1&#x02009;g, b.i.d. for ten days, or sequential treatment (ST) as follows: lansoprazole 30&#x02009;mg, amoxicillin and placebo 1.0&#x02009;g b.i.d for the first five days, followed by lansoprazole 30&#x02009;mg, clarithromycin 500&#x02009;mg, and tinidazole 500&#x02009;mg b.i.d, for the remaining five days. Eradication rates were determined 60 days after treatment by urease, histology, or <sup>13</sup>C-urea breath test. <italic>Results</italic>. In intention to treat (ITT) analysis, the rate of <italic>H. pylori</italic> eradication in the TT and ST groups was the same for both regimens as follows: 86% (43/50), 95% CI 93,3 to 73.4%. In Per protocol (PP) analysis, the rate of <italic>H. pylori</italic> eradication in the TT and ST groups was 87.8% (43/49), 95% CI 94,5 to 75.3% and 89.6% (43/48), 95% CI 95,8 to 77.3%, respectively. <italic>Conclusions</italic>. In Brazil, standard triple therapy is as equally effective as sequential therapy in eradicating <italic>Helicobacter pylori</italic> patients. This study was registered under Clinical Trials with number <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN62400496">ISRCTN62400496</ext-link>.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>There are several therapeutic regimens to eradicate<italic> H. pylori</italic>, involving bismuth, clarithromycin, amoxicillin, furazolidone, nitroimidazole compounds, quinolones, and proton pump inhibitors, in different combinations [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>].</p><p>The triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin) for seven days has been the most widely used regimen, recommended by many national and international consensus meetings [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. However, over the past several years a considerable drop in the eradication rates of<italic> H. pylori</italic> has been observed, reaching unacceptable levels (less than 80%) [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. This phenomenon has been reported by authors from all over the world due to a considerable increase in the prevalence of resistance to clarithromycin and metronidazole [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. In Brazil, this is also the situation, though in smaller scale [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>], because the susceptibility of strains of<italic> H. pylori</italic> to clarithromycin is still high [<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>]. The resistance to<italic> H. pylori</italic> varies from one country to another and also in different regions of the same country [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>In Europe and Asia, a new therapeutic regimen has been used for a few years. It is called sequential therapy, which consists of a double scheme, with a proton pump inhibitor + amoxicillin for five days, followed by a triple therapy with proton pump inhibitor, clarithromycin, and tinidazole for five additional days. The sequential therapy achieves around 90&#x02013;94% [<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>] eradication rates. These results, which although are already decreasing in effectiveness [<xref rid="B22" ref-type="bibr">22</xref>], have not yet been documented in Latin America [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>In Brazil, we have not heard of studies using this therapy as the first choice. The aim of this study was to compare the eradication rates of<italic> H. pylori</italic> using sequential therapy versus triple therapy over a period of ten days.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Study Design</title><p>This is a randomized, double-blind, prospective trial, performed from October 2012 to December 2013, which included patients from the Gastroenterology Department at the University of S&#x000e3;o Paulo, School of Medicine, Clinical Hospital. Patients at least 16 years old, who underwent an upper endoscopy due to dyspeptic symptoms and were found to have<italic> H. pylori</italic> infection confirmed by the rapid urease test and histology, were enrolled into this study. None of the patients received previous eradication treatment. Exclusion criteria included previous treatment for<italic> H. pylori</italic> and previous use of proton pump inhibitors, antibiotics, or chemotherapy in the four weeks that preceded the beginning of the trial. Patients who had undergone gastrectomy or had history of complicated ulcers (Forrest I and Forrest II), pregnant or breastfeeding women, and patients with consumptive diseases and with uncompensated kidney or heart failure were excluded as well. The study was performed in accordance with the Declaration of Helsinki and was approved by the institutional Ethics Review Board for clinical research. All patients signed an informed consent form. Patients whose<italic> H. pylori</italic> was not eradicated underwent retreatment with another therapeutic regimen.</p><p>Patients were randomized into two groups.<list list-type="alpha-lower"><list-item><p>Triple therapy (TT) for 10 days (30&#x02009;mg lansoprazole, 500&#x02009;mg clarithromycin, and 1.0&#x02009;g amoxicillin, each administered twice a day).</p></list-item><list-item><p>Sequential therapy (ST) for 10 days (30&#x02009;mg lansoprazole and 1.0&#x02009;g amoxicillin and placebo, each administered twice a day for five days, followed by 30&#x02009;mg lansoprazole, 500&#x02009;mg clarithromycin, and 500&#x02009;mg tinidazole, each administered twice a day for the remaining five days).</p></list-item></list>An independent researcher who was in charge of concealing the medication was responsible for generating a computer-based sequence of random numbers. For each group of patients were prepared pill boxes containing the medications and placebo indistinguishable from active medicine.</p></sec><sec id="sec2.2"><title>2.2. Procedures</title><p>Patients with dyspeptic symptoms underwent an upper endoscopy.<italic> H. pylori</italic> infection was determined by the rapid urease test [<xref rid="B24" ref-type="bibr">24</xref>] and histology [<xref rid="B25" ref-type="bibr">25</xref>], using gastric mucosal biopsies of the antrum and body. Patients with positive results in the two methods were included in the trial.<italic> H. pylori</italic> eradication was assessed at least two months after the end of the treatment by urease, histology, and <sup>13</sup>C-urea breath test in patients with peptic ulcer [<xref rid="B26" ref-type="bibr">26</xref>]. In functional dyspepsia patients, eradication was confirmed only through the <sup>13</sup>C-urea breath test. All patients were advised to suspend treatment with proton pump inhibitors or H<sub>2</sub> receptor antagonists, at least ten days prior to<italic> H. pylori</italic> testing.</p><p>The secondary goal of this study was to assess patients' adherence to treatment and possible adverse effects. Patients' adherence was determined by using capsule counting and considered satisfactory when more than 90% of the pills were taken. No questionnaires were used in this study.</p><p>This study was registered under Clinical Trials with number <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN62400496">ISRCTN62400496</ext-link>.</p></sec><sec id="sec2.3"><title>2.3. Statistical Analysis</title><p>Sample size was calculated using the Fisher exact test with expected eradication rates of 75% and 95% for TT and ST, respectively, considering an 80% power level and 5% significance level.</p><p>Descriptive analysis was presented as mean (&#x000b1;standard deviation) for quantitative variables and absolute numbers (percentages) for qualitative variables. The Mann-Whitney test for quantitative variables and Fisher's exact test for qualitative variables were used to compare the two groups as well as the 95% confidence intervals for the difference between triple therapy and sequential therapy eradication rates.</p><p>Intention to treat (ITT) and per protocol (PP) analysis were considered. A <italic>p</italic> value &#x0003c;0.05 indicates statistical significance.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Patients</title><p>One hundred patients with proved<italic> H. pylori</italic> infection were included in the trial. The baseline demographic and clinical characteristics of patients were similar in the 2 groups (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>Three patients who were excluded from the PP analysis are as follows: two discontinued because of adverse events (epigastric pain) and one was lost to follow-up.</p><p>All the patients in both groups adhered to the treatment (&#x0003e;90% of the medication was taken).</p></sec><sec id="sec3.2"><title>3.2. Clinical Efficacy</title><p>The eradication rates are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. There was no significant difference in the eradication rates between the Standard Triple Therapy and Sequential Therapy groups, in ITT and PP analysis.</p><p>Eighty-five patients were diagnosed with chronic gastritis and 15 with peptic ulcer disease (gastric ulcer or duodenal ulcer). Fifteen, out of the 97 patients who completed the study, had peptic ulcers and 82 had chronic gastritis; of these, 6 patients were using omeprazole, because of dyspeptic symptoms. The overall eradication rates in patients with chronic gastritis and those with peptic ulcer disease were 89.4% and 86.7% in the ITT analysis and 89.0% and 86.7% in PP analysis, respectively. There was no (ITT: <italic>p</italic> = 0.699; PP: <italic>p</italic> = 0.677) significant difference in the eradication rate between patients with chronic gastritis and those with peptic ulcer disease.</p></sec><sec id="sec3.3"><title>3.3. Adverse Events</title><p>Both treatments were well tolerated. There was no serious adverse event. Only two patients discontinued treatment because of adverse events (epigastric pain), one in the TT group and another in the ST group. <xref ref-type="table" rid="tab3"> Table 3</xref> shows the side effects.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The results of this trial demonstrated that<italic> H. pylori</italic> eradication rates were similar for both groups. No significant difference in eradication rates was found between patients with chronic gastritis and those with peptic ulcers. Also, we have not seen important adverse effects, and only two patients had to stop treatment due to epigastric pain (one in each group). Other symptoms such as nausea, diarrhea, vomiting, heartburn, bloating, headache, and bitter taste were of mild intensity and similar in frequency in both groups. Although not statistically significant, a greater percentage of adverse events were observed in the sequential therapy (48% &#x000d7; 34,6%, <italic>p</italic> = 0.219).</p><p>Several studies in the literature have shown that the effectiveness of the triple therapy has been declining over the past years [<xref rid="B27" ref-type="bibr">27</xref>], mainly due to an increase in clarithromycin resistance, especially in the USA and Europe [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. For this reason, several other regimens have been assessed. A commonly used scheme is sequential therapy, which consists of the administration of PPI and amoxicillin during the first stage and PPI + clarithromycin and imidazolium in the second stage, with eradication rates greater than 90% [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. In view of the latter results, sequential therapy has been recommended as the preferred treatment to eradicate<italic> H. pylori,</italic> especially in Europe.</p><p>In Brazil, we have not tested sequential therapy as an alternative regimen to triple therapy. Because of the high prevalence of<italic> H. pylori</italic> infection in Brazil, it is important to have other therapeutic regimens, which should be more effective, accessible to the population, with good adherence, fewer adverse effects, and low cost.</p><p>Unlike studies from other countries, our trial has not shown significant difference in the eradication rates between the two regimens. As previously mentioned, resistance to antibiotics, especially clarithromycin, is the main reason for the decrease in<italic> H. pylori</italic> eradication rates. However, it is important to know that this resistance varies from country to country and from region to region in the same country [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. This variation in resistance can influence the efficacy of<italic> H. pylori</italic> therapeutic regimens. In Brazil, resistance to clarithromycin is still relatively low, while to metronidazole, it is very common [<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Similar results were also found in other studies that were performed in Latin America [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B31" ref-type="bibr">31</xref>].</p><p>Another relevant factor to be considered is the cost of treatment. In Brazil, triple therapy is available in kits, with three drugs in the same packaging, which makes it easier for the patients to adhere to treatment. The cost of the triple therapy kit is U$ 60,00 on average, while the cost of sequential therapy is approximately U$ 130,00, more than twice as much. Moreover, there is no kit for sequential therapy.</p><p>Our trial has few limitations. We have not assessed<italic> H. pylori</italic> resistance to antibiotics through sensitivity tests, since it is a difficult test to perform in our community and, when available, it is still very costly for the patient.</p><p>New trials are necessary to assess if<italic> H. pylori</italic> in Brazil has a tendency to increase its resistance to clarithromycin. Until now, we have not observed these epidemiological trends, since our eradication rates in this trial were the same as we observed in a previous study that showed 88,8% and 82,7% eradication rates in peptic ulcer and functional dyspeptic patients, respectively [<xref rid="B16" ref-type="bibr">16</xref>].</p></sec><sec id="sec5"><title>5. Conclusion</title><p>In conclusion, our findings suggest that sequential therapy has not proven to be superior over triple therapy in eradicating<italic> H. pylori</italic> infection. Since it has satisfactory eradication rates, low cost, and less complexity for the patient, triple therapy is still a good first-line regimen to eradicate the<italic> H. pylori</italic> infection in Brazil.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Mrs. Cibele Villares Lopes (biological technician) who performed the urea breath tests. Drugs are supported by Medley Ind&#x000fa;stria Farmac&#x000ea;utica, S&#x000e3;o Paulo, Brazil.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors have no competing interests.</p></sec><sec><title>Authors' Contribution</title><p>All authors contributed to the design of the study and have read and approved the final paper. Acquisition of data and quality control were done by Jaime Natan Eisig, Christiane Haro, and Ana Cristina S&#x000e1; Teixeira. Analysis and interpretation of data were the responsibility of Jaime Natan Eisig, M&#x000e1;rcio Augusto Diniz, Fernando Marcuz Silva, Joaquim Prado Moraes-Filho, and Ronnie Fass. Endoscopic examinations were done by Ricardo Correa Barbuti, Tom&#x000e1;s Navarro-Rodriguez, and Decio Chinzon. Laboratory tests were the responsibility of Rejane Mattar, and Jaime Natan Eisig was responsible for the paper's draft.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unge</surname><given-names>P.</given-names></name><name><surname>Berstad</surname><given-names>A.</given-names></name></person-group><article-title>Pooled analysis of anti-<italic>Helicobacter pylori</italic> treatment regimens</article-title><source><italic>Scandinavian Journal of Gastroenterology, Supplement</italic></source><year>1996</year><volume>31</volume><issue>220</issue><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="other">2-s2.0-0029816488</pub-id><pub-id pub-id-type="pmid">8898433</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pipkin</surname><given-names>G. A.</given-names></name><name><surname>Williamson</surname><given-names>R.</given-names></name><name><surname>Wood</surname><given-names>J. R.</given-names></name></person-group><article-title>Review article: One-week clarithromycin triple therapy regimens for eradication of <italic>Helicobacter pylori</italic>
</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>1998</year><volume>12</volume><issue>9</issue><fpage>823</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1998.00405.x</pub-id><pub-id pub-id-type="other">2-s2.0-0031678670</pub-id><pub-id pub-id-type="pmid">9768524</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>N.</given-names></name><name><surname>Rao</surname><given-names>B. V.</given-names></name><name><surname>Rademaker</surname><given-names>J. W.</given-names></name><name><surname>Hunt</surname><given-names>R. H.</given-names></name></person-group><article-title>Meta-analysis of the efficacy of antibiotic therapy in eradicating <italic>Helicobacter pylori</italic>
</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>1992</year><volume>87</volume><issue>12</issue><fpage>1716</fpage><lpage>1727</lpage><pub-id pub-id-type="other">2-s2.0-0026486714</pub-id><pub-id pub-id-type="pmid">1449132</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cammarota</surname><given-names>G.</given-names></name><name><surname>Cianci</surname><given-names>R.</given-names></name><name><surname>Cannizzaro</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for <italic>Helicobacter pylori</italic> infection</article-title><source><italic>Alimentary Pharmacology &#x00026; Therapeutics</italic></source><year>2000</year><volume>14</volume><issue>10</issue><fpage>1339</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2000.00846.x</pub-id><pub-id pub-id-type="other">2-s2.0-0033790075</pub-id><pub-id pub-id-type="pmid">11012480</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>M.</given-names></name><name><surname>Khedmat</surname><given-names>H.</given-names></name><name><surname>Yari</surname><given-names>F.</given-names></name></person-group><article-title>Eradication rate of <italic>Helicobacter pylori</italic> in dyspeptic patients</article-title><source><italic>Medical Science Monitor</italic></source><year>2005</year><volume>11</volume><issue>4</issue><fpage>CR193</fpage><lpage>CR195</lpage><pub-id pub-id-type="other">2-s2.0-17444425335</pub-id><pub-id pub-id-type="pmid">15795700</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicente</surname><given-names>R.</given-names></name><name><surname>Sicilia</surname><given-names>B.</given-names></name><name><surname>Gallego</surname><given-names>S.</given-names></name><name><surname>Revillo</surname><given-names>M. J.</given-names></name><name><surname>Duc&#x000f3;ns</surname><given-names>J.</given-names></name><name><surname>Gomoll&#x000f3;n</surname><given-names>F.</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> eradication in patients with peptic ulcer after two treatments failure: A prospective culture-guided study</article-title><source><italic>Gastroenterologia y Hepatologia</italic></source><year>2002</year><volume>25</volume><issue>7</issue><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/s0210-5705(02)70283-5</pub-id><pub-id pub-id-type="other">2-s2.0-0036704693</pub-id><pub-id pub-id-type="pmid">12139836</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>L. G.</given-names></name><name><surname>Maguinilk</surname><given-names>I.</given-names></name><name><surname>Zaterka</surname><given-names>S.</given-names></name><name><surname>Parente</surname><given-names>J. M.</given-names></name><name><surname>Passos</surname><given-names>M. D. C. F.</given-names></name><name><surname>Moraes-Filho</surname><given-names>J. P. P.</given-names></name></person-group><article-title>3rd Brazilian consensus on <italic>Helicobacter pylori</italic>
</article-title><source><italic>Arquivos de Gastroenterologia</italic></source><year>2013</year><volume>50</volume><issue>2</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="other">2-s2.0-84880059244</pub-id><pub-id pub-id-type="pmid">23657298</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P.</given-names></name><name><surname>Megraud</surname><given-names>F.</given-names></name><name><surname>O'Morain</surname><given-names>C. A.</given-names></name><etal/></person-group><article-title>Management of <italic>Helicobacter pylori</italic> infection&#x02014;the Maastricht IV/ Florence consensus report</article-title><source><italic>Gut</italic></source><year>2012</year><volume>61</volume><issue>5</issue><fpage>646</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-302084</pub-id><pub-id pub-id-type="other">2-s2.0-84859589351</pub-id><pub-id pub-id-type="pmid">22491499</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumurdulu</surname><given-names>Y.</given-names></name><name><surname>Serin</surname><given-names>E.</given-names></name><name><surname>&#x000d6;zer</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Low eradication rate of <italic>Helicobacter pylori</italic> with triple 7&#x02013;14 days and quadriple therapy in Turkey</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2004</year><volume>10</volume><issue>5</issue><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="other">2-s2.0-12144289669</pub-id><pub-id pub-id-type="pmid">14991935</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>D. Y.</given-names></name><name><surname>Fischbach</surname><given-names>L.</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> treatment in the era of increasing antibiotic resistance</article-title><source><italic>Gut</italic></source><year>2010</year><volume>59</volume><issue>8</issue><fpage>1143</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.192757</pub-id><pub-id pub-id-type="other">2-s2.0-77954704743</pub-id><pub-id pub-id-type="pmid">20525969</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;graud</surname><given-names>F.</given-names></name></person-group><article-title>
<italic>H pylori</italic> antibiotic resistance: prevalence, importance, and advances in testing</article-title><source><italic>Gut</italic></source><year>2004</year><volume>53</volume><issue>9</issue><fpage>1374</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.022111</pub-id><pub-id pub-id-type="other">2-s2.0-4344592305</pub-id><pub-id pub-id-type="pmid">15306603</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendon&#x000e7;a</surname><given-names>S.</given-names></name><name><surname>Ecclissato</surname><given-names>C.</given-names></name><name><surname>Sartori</surname><given-names>M. S.</given-names></name><etal/></person-group><article-title>Prevalence of <italic>Helicobacter pylori</italic> resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil</article-title><source><italic>Helicobacter</italic></source><year>2000</year><volume>5</volume><issue>2</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1046/j.1523-5378.2000.00011.x</pub-id><pub-id pub-id-type="other">2-s2.0-0034583821</pub-id><pub-id pub-id-type="pmid">10849055</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prazeres Magalh&#x000e3;es</surname><given-names>P.</given-names></name><name><surname>De Magalh&#x000e3;es Queiroz</surname><given-names>D. M.</given-names></name><name><surname>Campos Barbosa</surname><given-names>D. V.</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> primary resistance to metronidazole and clarithromycin in Brazil</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2002</year><volume>46</volume><issue>6</issue><fpage>2021</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1128/aac.46.6.2021-2023.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036096003</pub-id><pub-id pub-id-type="pmid">12019131</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisig</surname><given-names>J. N.</given-names></name><name><surname>Silva</surname><given-names>F. M.</given-names></name><name><surname>Barbuti</surname><given-names>R. C.</given-names></name><name><surname>Navarro-Rodriguez</surname><given-names>T.</given-names></name><name><surname>Moraes-Filho</surname><given-names>J. P. P.</given-names></name><name><surname>Pedrazzoli</surname><given-names>J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>
<italic>Helicobacter pylori</italic> antibiotic resistance in Brazil: clarithromycin is still a good option</article-title><source><italic>Arquivos de Gastroenterologia</italic></source><year>2011</year><volume>48</volume><issue>4</issue><fpage>261</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1590/s0004-28032011000400008</pub-id><pub-id pub-id-type="other">2-s2.0-83355173182</pub-id><pub-id pub-id-type="pmid">22147131</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisig</surname><given-names>J. N.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>S. B.</given-names></name><name><surname>Silva</surname><given-names>F. M.</given-names></name><name><surname>Hashimoto</surname><given-names>C.</given-names></name><name><surname>Pinto Moraes-Filho</surname><given-names>J. P.</given-names></name><name><surname>Laudanna</surname><given-names>A. A.</given-names></name></person-group><article-title>The impact of <italic>Helicobacter pylori</italic> resistance on the efficacy of a short course pantoprazole based triple therapy</article-title><source><italic>Arquivos de Gastroenterologia</italic></source><year>2003</year><volume>40</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1590/s0004-28032003000100012</pub-id><pub-id pub-id-type="other">2-s2.0-0345305824</pub-id><pub-id pub-id-type="pmid">14534667</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felga</surname><given-names>G.</given-names></name><name><surname>Silva</surname><given-names>F. M.</given-names></name><name><surname>Barbuti</surname><given-names>R. C.</given-names></name><name><surname>Navarro-Rodriguez</surname><given-names>T.</given-names></name><name><surname>Zaterka</surname><given-names>S.</given-names></name><name><surname>Eisig</surname><given-names>J. N.</given-names></name></person-group><article-title>Clarithromycin-based triple therapy for <italic>Helicobacter pylori</italic> treatment in peptic ulcer patients</article-title><source><italic>Journal of Infection in Developing Countries</italic></source><year>2010</year><volume>4</volume><issue>11</issue><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="other">2-s2.0-78650374940</pub-id><pub-id pub-id-type="pmid">21252448</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N.</given-names></name></person-group><article-title>Are there geographical and regional differences in <italic>Helicobacter pylori</italic> eradication?</article-title><source><italic>Canadian Journal of Gastroenterology</italic></source><year>2003</year><volume>17</volume><issue>supplement B</issue><fpage>30B</fpage><lpage>32B</lpage><pub-id pub-id-type="other">2-s2.0-2142763982</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaira</surname><given-names>D.</given-names></name><name><surname>Zullo</surname><given-names>A.</given-names></name><name><surname>Vakil</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Sequential therapy versus standard triple-drug therapy for <italic>Helicobacter pylori</italic> eradication: a randomized trial</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2007</year><volume>146</volume><issue>8</issue><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-8-200704170-00006</pub-id><pub-id pub-id-type="other">2-s2.0-34247646200</pub-id><pub-id pub-id-type="pmid">17438314</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>L.</given-names></name><name><surname>Vakil</surname><given-names>N.</given-names></name><name><surname>Leandro</surname><given-names>G.</given-names></name><name><surname>Di Mario</surname><given-names>F.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name></person-group><article-title>Sequential therapy or triple therapy for <italic>Helicobacter pylori</italic> infection: systematic review and meta-analysis of randomized controlled trials in adults and children</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2009</year><volume>104</volume><issue>12</issue><fpage>3069</fpage><lpage>3079</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.555</pub-id><pub-id pub-id-type="other">2-s2.0-72949096113</pub-id><pub-id pub-id-type="pmid">19844205</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>P. I.</given-names></name><name><surname>Wu</surname><given-names>D.-C.</given-names></name><name><surname>Wu</surname><given-names>J.-Y.</given-names></name><name><surname>Graham</surname><given-names>D. Y.</given-names></name></person-group><article-title>Is there a benefit to extending the duration of <italic>Helicobacter pylori</italic> sequential therapy to 14 days?</article-title><source><italic>Helicobacter</italic></source><year>2011</year><volume>16</volume><issue>2</issue><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00829.x</pub-id><pub-id pub-id-type="other">2-s2.0-79952716248</pub-id><pub-id pub-id-type="pmid">21435093</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmiloviz-Weiss</surname><given-names>H.</given-names></name><name><surname>Shalev</surname><given-names>T.</given-names></name><name><surname>Chechoulin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>High eradication rates of <italic>Helicobacter pylori</italic> infection following sequential therapy: the Israeli experience treating na&#x000ef;ve patients</article-title><source><italic>Helicobacter</italic></source><year>2011</year><volume>16</volume><issue>3</issue><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00834.x</pub-id><pub-id pub-id-type="other">2-s2.0-79956084995</pub-id><pub-id pub-id-type="pmid">21585609</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>L.</given-names></name><name><surname>Vakil</surname><given-names>N.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name><name><surname>Scarpignato</surname><given-names>C.</given-names></name></person-group><article-title>Global eradication rates for <italic>Helicobacter pylori</italic> infection: systematic review and meta-analysis of sequential therapy</article-title><source><italic>British Medical Journal</italic></source><year>2013</year><volume>347</volume><issue>7920</issue><pub-id pub-id-type="publisher-id">f4587</pub-id><pub-id pub-id-type="doi">10.1136/bmj.f4587</pub-id><pub-id pub-id-type="other">2-s2.0-84882442131</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>E. R.</given-names></name><name><surname>Anderson</surname><given-names>G. L.</given-names></name><name><surname>Morgan</surname><given-names>D. R.</given-names></name><etal/></person-group><article-title>14-day triple, 5-day concomitant, and 10-day sequential therapies for <italic>Helicobacter pylori</italic> infection in seven Latin American sites: a randomised trial</article-title><source><italic>The Lancet</italic></source><year>2011</year><volume>378</volume><issue>9790</issue><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(11)60825-8</pub-id><pub-id pub-id-type="other">2-s2.0-80051472277</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattar</surname><given-names>R.</given-names></name><name><surname>Dos Santos</surname><given-names>A. F.</given-names></name><name><surname>Eisig</surname><given-names>J. N.</given-names></name><etal/></person-group><article-title>No correlation of babA2 with vacA and cagA genotypes of <italic>Helicobacter pylori</italic> and grading of gastritis from peptic ulcer disease patients in Brazil</article-title><source><italic>Helicobacter</italic></source><year>2005</year><volume>10</volume><issue>6</issue><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2005.00360.x</pub-id><pub-id pub-id-type="other">2-s2.0-27944510241</pub-id><pub-id pub-id-type="pmid">16302986</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattar</surname><given-names>R.</given-names></name><name><surname>Marques</surname><given-names>S. B.</given-names></name><name><surname>dos Santos</surname><given-names>A. F.</given-names></name><name><surname>Monteiro</surname><given-names>M. D. S.</given-names></name><name><surname>Iriya</surname><given-names>K.</given-names></name><name><surname>Carrilho</surname><given-names>F. J.</given-names></name></person-group><article-title>A possible role of IL-1RN gene polymorphism in the outcome of gastrointestinal diseases associated with <italic>H. pylori</italic> infection</article-title><source><italic>Clinical and Experimental Gastroenterology</italic></source><year>2013</year><volume>6</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2147/ceg.s42260</pub-id><pub-id pub-id-type="other">2-s2.0-84876481210</pub-id><pub-id pub-id-type="pmid">23637547</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>J. M. K.</given-names></name><name><surname>Villares</surname><given-names>C. A.</given-names></name><name><surname>Monteiro</surname><given-names>M.-D. S.</given-names></name><name><surname>Cola&#x000fa;to</surname><given-names>C.</given-names></name><name><surname>dos Santos</surname><given-names>A. F.</given-names></name><name><surname>Mattar</surname><given-names>R.</given-names></name></person-group><article-title>Validation of a rapid stool antigen test for diagnosis of <italic>Helicobacter pylori</italic> infection</article-title><source><italic>Revista do Instituto de Medicina Tropical de S&#x000e3;o Paulo</italic></source><year>2010</year><volume>52</volume><issue>3</issue><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1590/s0036-46652010000300002</pub-id><pub-id pub-id-type="other">2-s2.0-77954847429</pub-id><pub-id pub-id-type="pmid">20602020</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>A.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name><name><surname>Gisbert</surname><given-names>J. P.</given-names></name><name><surname>O'Morain</surname><given-names>C.</given-names></name></person-group><article-title>Treatment of <italic>Helicobacter pylori</italic> infection 2014</article-title><source><italic>Helicobacter</italic></source><year>2014</year><volume>19</volume><issue>supplement 1</issue><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/hel.12163</pub-id><pub-id pub-id-type="pmid">25167944</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N.</given-names></name><name><surname>Lanza</surname><given-names>F.</given-names></name><name><surname>Schwartz</surname><given-names>H.</given-names></name><name><surname>Barth</surname><given-names>J.</given-names></name></person-group><article-title>Seven-day therapy for <italic>Helicobacter pylori</italic> in the United States</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2004</year><volume>20</volume><issue>1</issue><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.02029.x</pub-id><pub-id pub-id-type="other">2-s2.0-3142696806</pub-id><pub-id pub-id-type="pmid">15225176</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duck</surname><given-names>W. M.</given-names></name><name><surname>Sobel</surname><given-names>J.</given-names></name><name><surname>Pruckler</surname><given-names>J. M.</given-names></name><etal/></person-group><article-title>Antimicrobial resistance incidence risk and factors among <italic>Helicobacter pylori</italic>-infected persons, United States</article-title><source><italic>Emerging Infectious Diseases</italic></source><year>2004</year><volume>10</volume><issue>6</issue><fpage>1088</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.3201/eid1006.030744</pub-id><pub-id pub-id-type="other">2-s2.0-2542580999</pub-id><pub-id pub-id-type="pmid">15207062</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buz&#x000e1;s</surname><given-names>G. M.</given-names></name><name><surname>Lotz</surname><given-names>G.</given-names></name><name><surname>Kiss</surname><given-names>A.</given-names></name></person-group><article-title>The epidemiology of clarithromycin resistance of <italic>Helicobacter pylori</italic> infection in Hungary</article-title><source><italic>Orvosi Hetilap</italic></source><year>2007</year><volume>148</volume><issue>31</issue><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1556/oh.2007.28013</pub-id><pub-id pub-id-type="pmid">17656336</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo-Gamarra</surname><given-names>V.</given-names></name><name><surname>Rodriguez-Ulhoa</surname><given-names>C.</given-names></name><name><surname>Diaz-Velez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Sa 1914 sequential versus triple standard therapy for <italic>Helicobacter pylori</italic> eradication</article-title><source><italic>Gastroenterology</italic></source><year>2013</year><volume>144</volume><issue>5</issue><fpage>p. S-333</fpage></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristic of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Triple therapy<break/>(<italic>n</italic> = 50)<break/>
<italic>N</italic>/%</th><th align="center" rowspan="1" colspan="1">Sequential therapy<break/>(<italic>n</italic> = 50)<break/>
<italic>N</italic>/%</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age </td><td align="center" rowspan="1" colspan="1">50.2 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">44.2 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender: female</td><td align="center" rowspan="1" colspan="1">32 (64%)</td><td align="center" rowspan="1" colspan="1">40 (80%)</td><td align="center" rowspan="1" colspan="1">0.118</td></tr><tr><td align="left" rowspan="1" colspan="1">Cigarette smoking</td><td align="center" rowspan="1" colspan="1">17 (34%)</td><td align="center" rowspan="1" colspan="1">11 (22%)</td><td align="center" rowspan="1" colspan="1">0.695</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol drinking</td><td align="center" rowspan="1" colspan="1">6 (12%)</td><td align="center" rowspan="1" colspan="1">2 (4%)</td><td align="center" rowspan="1" colspan="1">0.269</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic gastritis</td><td align="center" rowspan="1" colspan="1">41 (82%)</td><td align="center" rowspan="1" colspan="1">44 (88%)</td><td align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" rowspan="1" colspan="1">Duodenal ulcer </td><td align="center" rowspan="1" colspan="1">5 (10%)</td><td align="center" rowspan="1" colspan="1">4 (8%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric ulcer</td><td align="center" rowspan="1" colspan="1">4 (8%)</td><td align="center" rowspan="1" colspan="1">2 (4%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>
<italic>Helicobacter pylori</italic> eradication rates with triple and sequential therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Triple</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Sequential</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic> value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Intention to treat</td><td align="center" rowspan="1" colspan="1">86.0% (43/50) </td><td align="center" rowspan="1" colspan="1">93.3&#x02013;73.4</td><td align="center" rowspan="1" colspan="1">86.0% (43/50)</td><td align="center" rowspan="1" colspan="1">93.3&#x02013;73.4</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Per protocol</td><td align="center" rowspan="1" colspan="1">87.8% (43/49)</td><td align="center" rowspan="1" colspan="1">94.5&#x02013;75.3</td><td align="center" rowspan="1" colspan="1">89.6% (43/48)</td><td align="center" rowspan="1" colspan="1">95.8&#x02013;77.3</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Patients with self-reported adverse events during therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Adverse event</th><th align="center" rowspan="1" colspan="1">Triple therapy</th><th align="center" rowspan="1" colspan="1">Sequential therapy</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value </th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>N</italic>/%</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>/%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Epigastric pain</td><td align="center" rowspan="1" colspan="1">3 (6.12%)</td><td align="center" rowspan="1" colspan="1">4 (8.33%)</td><td align="center" rowspan="1" colspan="1">0.715</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">3 (6.12%)</td><td align="center" rowspan="1" colspan="1">5 (10.42%)</td><td align="center" rowspan="1" colspan="1">0.487</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="center" rowspan="1" colspan="1">5 (10.2%)</td><td align="center" rowspan="1" colspan="1">6 (12.5%)</td><td align="center" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">2 (4.08%)</td><td align="center" rowspan="1" colspan="1">1 (2.08%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Bloating</td><td align="center" rowspan="1" colspan="1">2 (4.08%)</td><td align="center" rowspan="1" colspan="1">3 (6.25%)</td><td align="center" rowspan="1" colspan="1">0.678</td></tr><tr><td align="left" rowspan="1" colspan="1">Heartburn</td><td align="center" rowspan="1" colspan="1">1 (2.04%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1 (2.08%)</td><td align="center" rowspan="1" colspan="1">0.495</td></tr><tr><td align="left" rowspan="1" colspan="1">Bitter taste</td><td align="center" rowspan="1" colspan="1">1 (2.04%)</td><td align="center" rowspan="1" colspan="1">3 (6.25%)</td><td align="center" rowspan="1" colspan="1">0.362</td></tr></tbody></table></table-wrap></floats-group></article>